Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice

Nonsteroidal anti-inflammatory drugs decrease sporadic colorectal carcinoma and adenomas in patients with familial adenomatous polyposis and in rodent models of sporadic colon cancer and familial adenomatous polyposis. Similarly, selective cyclooxygenase 2 inhibitors decrease adenomas in humans and rodents. However, their effects on chronic colitis and colitis-associated neoplasia are unknown. Interleukin 10(-/-) mice (C57/B6) were fed regular chow (n=20) or chow with celecoxib (1,500 ppm, n=18) or rofecoxib (75 ppm, n=20) for 12 weeks. Twenty-eight percent of the celecoxib group died versus 5% of the control and rofecoxib groups (p<0.05 compared with control). Celecoxib and rofecoxib increased the incidence of colitis (26% vs. 92% and 68%, p<0.01), colitis score (0.4+/-0.2 vs. 2.5+/-0.3 and 2+/-0.4, p<0.01), aberrant crypt foci (0.5±0.3 vs. 3.7±2.6 and 2.8±0.7, p<0.01), aberrant crypts per mouse (4.11+/-2.1 vs. 41.2+/-9.7 and 27.1+/-7.5, p<0.01) and dysplasia (11% vs. 54% and 42%, p<0.01). Similarly, indomethacin (9 ppm, n=15) increased colitis score, aberrant crypt foci, and dysplasia after 27 days of treatment. Two selective cyclooxygenase 2 inhibitors exacerbate colitis and premalignant changes in the interleukin 10(-/-) mouse model of chronic colitis and colitis-associated colon carcinoma.